Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).